scholarly journals Model‐Based Approach to Improve Clinical Outcomes in Neonates With Opioid Withdrawal Syndrome Using Real‐World Data

2020 ◽  
Vol 109 (1) ◽  
pp. 243-252
Author(s):  
Nadeesri Wijekoon ◽  
Oluwatobi Aduroja ◽  
Jessica M. Biggs ◽  
Dina El‐Metwally ◽  
Mathangi Gopalakrishnan
Keyword(s):  
Clinical Outcomes ◽  
Real World ◽  
Withdrawal Syndrome ◽  
Opioid Withdrawal ◽  
Real World Data ◽  
World Data ◽  
Model Based ◽  
Opioid Withdrawal Syndrome

scholarly journals Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma

Liver Cancer ◽  
2021 ◽  
pp. 1-16
Author(s):  
Xin Hui Chew ◽  
Rehena Sultana ◽  
Eshani N. Mathew ◽  
David Chee Eng Ng ◽  
Richard H.G. Lo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Compliance Rate ◽  
Locally Advanced ◽  
Consensus Guidelines ◽  
Real World Data ◽  
World Data ◽  
Cancer Centre

<b><i>Introduction:</i></b> Real-world management of patients with hepatocellular carcinoma (HCC) is crucially challenging in the current rapidly evolving clinical environment which includes the need for respecting patient preferences and autonomy. In this context, regional/national treatment guidelines nuanced to local demographics have increasing importance in guiding disease management. We report here real-world data on clinical outcomes in HCC from a validation of the Consensus Guidelines for HCC at the National Cancer Centre Singapore (NCCS). <b><i>Method:</i></b> We evaluated the NCCS guidelines using prospectively collected real-world data, comparing the efficacy of treatment received using overall survival (OS) and progression-free survival (PFS). Treatment outcomes were also independently evaluated against 2 external sets of guidelines, the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC). <b><i>Results:</i></b> Overall treatment compliance to the NCCS guidelines was 79.2%. Superior median OS was observed in patients receiving treatment compliant with NCCS guidelines for early (nonestimable vs. 23.5 months <i>p</i> &#x3c; 0.0001), locally advanced (28.1 vs. 22.2 months <i>p</i> = 0.0216) and locally advanced with macrovascular invasion (10.3 vs. 3.3 months <i>p</i> = 0.0013) but not for metastatic HCC (8.1 vs. 6.8 months <i>p</i> = 0.6300), but PFS was similar. Better clinical outcomes were seen in BCLC C patients who received treatment compliant with NCCS guidelines than in patients with treatment only allowed by BCLC guidelines (median OS 14.2 vs. 7.4 months <i>p</i> = 0.0002; median PFS 6.1 vs. 4.0 months <i>p</i> = 0.0286). Clinical outcomes were, however, similar for patients across all HKLC stages receiving NCCS-recommended treatment regardless of whether their treatment was allowed by HKLC. <b><i>Conclusion:</i></b> The high overall compliance rate and satisfactory clinical outcomes of patients managed according to the NCCS guidelines confirm its validity. This validation using real-world data considers patient and treating clinician preferences, thus providing a realistic analysis of the usefulness of the NCCS guidelines when applied in the clinics.

scholarly journals Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries

2019 ◽  
Vol 38 (11) ◽  
pp. 3049-3059 ◽  
Author(s):  
Rieke Alten ◽  
Eugen Feist ◽  
Hanns-Martin Lorenz ◽  
Hubert Nüßlein ◽  
Reinhard E. Voll ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Outcomes ◽  
Real World ◽  
Real World Data ◽  
World Data

Abstract WP6: Real-World Data on Reperfusion: Evidence of Good Outcomes in the International Trevo Retriever Registry

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
David S Liebeskind ◽  
Graham W Woolf ◽  
Bin Xiang ◽  
Ryan Shields ◽  
Erol Veznedaroglu ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Real World ◽  
Clinical Laboratory ◽  
Arterial Occlusion ◽  
Real World Data ◽  
Open Label ◽  
Endovascular Thrombectomy ◽  
World Data ◽  
Randomized Controlled ◽  
Male Sex

Background: Endovascular thrombectomy trials established efficacy in acute ischemic stroke, yet real-world data on device effectiveness is warranted. Core lab adjudication of angiography is required to validate reperfusion, providing evidence and detailed data beyond randomized, controlled trials. We report the largest endovascular therapy registry data linking independent core lab data on reperfusion with clinical outcomes. Methods: The Trevo Retriever Registry is a prospective, open-label, consecutive enrollment, multicenter, international registry with more than 65 enrolling sites worldwide. An independent Imaging Core Lab, blind to all other data, evaluates the angiography with a battery of various TICI scores (mTICI, oTICI, oTICI2C) to define reperfusion. Statistical analyses examined TICI reperfusion and association with clinical outcomes considering expansive data collected in the registry. Results: 506 enrolled subjects (mean age 68.2 ± 14.2 yrs; 53% female) had core lab adjudicated angiography as of July 2016, including 21.5% > 80 years old. Baseline NIHSS was median 15.0 (9.0, 20.0) with time from onset to CT of median 4.0 (1.7, 9.7) hrs. Core lab adjudicated arterial occlusion sites were: 53% M1, 24% ICA, 16% M2, 4% Basilar and 2% other. Time to reperfusion (oTICI ≥ 2A) was median 30.0 (19.0, 42.0) min. Core lab adjudicated revascularization was mTICI ≥ 2B in 90.4% (95%CI 87.4, 92.9), oTICI ≥ 2B in 82.3% (95%CI 78.6, 85.6) and oTICI2C ≥ 2C in 45.0% (95%CI 40.5, 49.6). mRS of 0-2 at 90 days was achieved in 57.3% (95%CI 52.5, 62.1). Extensive clinical, laboratory and stroke workflow variables were considered, yet only male sex (OR 0.62 (95% CI 0.38, 0.99) was an independent predictor of successful reperfusion (oTICI ≥ 2B) while age (OR 0.96 (95% CI 0.94, 0.97), NIHSS (OR 0.91 (95% CI 0.88, 0.94) and diabetes (OR 0.54 (95% CI 0.33, 0.88) predicted mRS 0-2 at 90 days. Conclusions: Proven reperfusion rates after endovascular stroke therapy excel in the real-world translation of thrombectomy devices around the globe, leading to good outcomes after stroke.

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study

2019 ◽  
Vol 170 (5-6) ◽  
pp. 132-140 ◽  
Author(s):  
Peter Peichl ◽  
Rieke Alten ◽  
Mauro Galeazzi ◽  
Hanns-Martin Lorenz ◽  
Hubert Nüßlein ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Outcomes ◽  
Real World ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document